PLx Pharma Winddown Valuation

Is 1D5A undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1D5A when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 1D5A's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 1D5A's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1D5A?

Key metric: As 1D5A is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 1D5A. This is calculated by dividing 1D5A's market cap by their current revenue.
What is 1D5A's PS Ratio?
PS Ratio	0.001x
Sales	US$4.54m
Market Cap	US$5.83k

1D5A key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 1D5A's PS Ratio compare to its peers?

The above table shows the PS ratio for 1D5A vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	0.02x
RLBD Real Brands	0.07x	n/a	US$2.7k
BLMS Bloomios	0.0008x	n/a	US$6.8k
VIVX.F Avivagen	0.02x	n/a	US$7.8k
PA8K Paion	0.003x	n/a	€44.2k
1D5A PLx Pharma Winddown	0.001x	n/a	€5.8k

Price-To-Sales vs Peers: 1D5A is good value based on its Price-To-Sales Ratio (0x) compared to the peer average (0x).

Price to Sales Ratio vs Industry

How does 1D5A's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?

24 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	2.9x	3.4%
1D5A PLx Pharma Winddown	0.001x	n/a	US$5.83k

24 Companies		Estimated Growth	Market Cap
Industry Avg.	2.9x	21.6%
1D5A PLx Pharma Winddown	0.001x	n/a	US$5.83k

No more companies

Price-To-Sales vs Industry: 1D5A is good value based on its Price-To-Sales Ratio (0x) compared to the European Pharmaceuticals industry average (3x).

Price to Sales Ratio vs Fair Ratio

What is 1D5A's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1D5A PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.001x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 1D5A's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Aspen Pharmacare Holdings

R75.5b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R8.95

0.6%

4.7%

Fortrea Holdings

US$1.8b

A contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide.

K67

US$18.40

-1.6%

-38.3%

Almirall

€1.8b

A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.

E2Z

€8.29

-1.8%

0.2%